journal
MENU ▼
Read by QxMD icon Read
search

Lancet Haematology

journal
https://www.readbyqxmd.com/read/28917657/oral-all-trans-retinoic-acid-plus-danazol-versus-danazol-as-second-line-treatment-in-adults-with-primary-immune-thrombocytopenia-a-multicentre-randomised-open-label-phase-2-trial
#1
Fei-Er Feng, Ru Feng, Min Wang, Jia-Min Zhang, Hao Jiang, Qian Jiang, Jin Lu, Hui Liu, Jun Peng, Ming Hou, Jian-Liang Shen, Jing-Wen Wang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Hui Zhang
BACKGROUND: Primary immune thrombocytopenia is a severe bleeding disorder. About 50-85% of patients achieve initial remission from first-line therapies, but optimal second-line treatment remains a challenge. All-trans retinoic acid (ATRA) has an immunomodulatory effect on haemopoiesis, making it a possible treatment option. We aimed to evaluate the efficacy and safety of ATRA plus danazol versus danazol in non-splenectomised patients with corticosteroid-resistant or relapsed primary immune thrombocytopenia...
September 13, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28917656/is-oral-all-trans-retinoic-acid-plus-danazol-a-refinement-of-second-line-therapy-for-primary-immune-thrombocytopenia-in-adults
#2
Simon Panzer, Ingrid Pabinger
No abstract text is available yet for this article.
September 13, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28916312/lenalidomide-maintenance-in-high-risk-chronic-lymphocytic-leukaemia-practice-changing-study-or-hypothesis-generating-approach
#3
Davide Rossi, Adalgisa Condoluci
No abstract text is available yet for this article.
September 12, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28916311/lenalidomide-maintenance-after-first-line-therapy-for-high-risk-chronic-lymphocytic-leukaemia-cllm1-final-results-from-a-randomised-double-blind-phase-3-study
#4
Anna Maria Fink, Jasmin Bahlo, Sandra Robrecht, Othman Al-Sawaf, Ali Aldaoud, Holger Hebart, Kathleen Jentsch-Ullrich, Steffen Dörfel, Kirsten Fischer, Clemens-Martin Wendtner, Thomas Nösslinger, Paolo Ghia, Francesc Bosch, Arnon P Kater, Hartmut Döhner, Michael Kneba, Karl-Anton Kreuzer, Eugen Tausch, Stephan Stilgenbauer, Matthias Ritgen, Sebastian Böttcher, Barbara Eichhorst, Michael Hallek
BACKGROUND: The combined use of genetic markers and detectable minimal residual disease identifies patients with chronic lymphocytic leukaemia with poor outcome after first-line chemoimmunotherapy. We aimed to assess lenalidomide maintenance therapy in these high-risk patients. METHODS: In this randomised, double-blind, phase 3 study (CLLM1; CLL Maintenance 1 of the German CLL Study Group), patients older than 18 years and diagnosed with immunophenotypically confirmed chronic lymphocytic leukaemia with active disease, who responded to chemoimmunotherapy 2-5 months after completion of first-line therapy and who were assessed as having a high risk for an early progression with at least a partial response after four or more cycles of first-line chemoimmunotherapy, were eligible if they had high minimal residual disease levels or intermediate levels combined with an unmutated IGHV gene status or TP53 alterations...
September 12, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28919087/outcomes-of-restrictive-versus-liberal-transfusion-strategies-in-older-adults-from-nine-randomised-controlled-trials-a-systematic-review-and-meta-analysis
#5
Geoff I Simon, Alison Craswell, Ogilvie Thom, Yoke Lin Fung
BACKGROUND: Guidelines for patient blood management recommend restrictive transfusion practice for most adult patients. These guidelines are supported by evidence from randomised controlled trials (RCTs); however, one of the patient groups not explicitly examined in these studies is the geriatric population. We examined RCTs relevant to transfusion outcomes in older patients. Our aim was to determine whether special guidelines are warranted for geriatric patients, recognising the different pathophysiological characteristics of this group...
September 11, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28919086/authors-reply-to-comment-blood-transfusion-strategies-in-elderly-patients
#6
LETTER
Geoff I Simon, Alison Craswell, Ogilvie Thom, Yoke Lin Fung
No abstract text is available yet for this article.
September 11, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28919085/blood-transfusion-strategies-in-elderly-patients
#7
Michael F Murphy, Lise Estcourt, Lawrence Tim Goodnough
No abstract text is available yet for this article.
September 11, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28826617/updated-analysis-of-calgb-alliance-100104
#8
Mario Boccadoro
No abstract text is available yet for this article.
August 17, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28826616/updated-analysis-of-calgb-alliance-100104-assessing-lenalidomide-versus-placebo-maintenance-after-single-autologous-stem-cell-transplantation-for-multiple-myeloma-a-randomised-double-blind-phase-3-trial
#9
Sarah A Holstein, Sin-Ho Jung, Paul G Richardson, Craig C Hofmeister, David D Hurd, Hani Hassoun, Sergio Giralt, Edward A Stadtmauer, Daniel J Weisdorf, Ravi Vij, Jan S Moreb, Natalie S Callander, Koen van Besien, Teresa G Gentile, Luis Isola, Richard T Maziarz, Asad Bashey, Heather Landau, Thomas Martin, Muzaffar H Qazilbash, Cesar Rodriguez, Brian McClune, Robert L Schlossman, Scott E Smith, Vera Hars, Kouros Owzar, Chen Jiang, Molly Boyd, Chelsea Schultz, Marcia Wilson, Parameswaran Hari, Marcelo C Pasquini, Mary M Horowitz, Thomas C Shea, Steven M Devine, Charles Linker, Kenneth C Anderson, Philip L McCarthy
BACKGROUND: In the CALGB (Alliance) 100104 study, lenalidomide versus placebo after autologous stem-cell transplantation (ASCT) was investigated for patients with newly diagnosed myeloma. That study showed improved time to progression and overall survival and an increase in second primary malignancies for lenalidomide at a median follow-up of 34 months. Here we report an updated intention-to-treat analysis of CALGB (Alliance) 100104 at a median follow-up of 91 months. METHODS: Patients were eligible for this randomised, double-blind, placebo-controlled, phase 3 trial if they had symptomatic disease requiring treatment; had received, at most, two induction regimens; and had achieved stable disease or better in the first 100 days after ASCT...
August 17, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28754272/correction-to-lancet-haematol-2017-4-e362-73
#10
(no author information available yet)
No abstract text is available yet for this article.
July 25, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28733186/easix-in-patients-with-acute-graft-versus-host-disease-a-retrospective-cohort-analysis
#11
Thomas Luft, Axel Benner, Sonata Jodele, Christopher E Dandoy, Rainer Storb, Ted Gooley, Brenda M Sandmaier, Natalia Becker, Aleksandar Radujkovic, Peter Dreger, Olaf Penack
BACKGROUND: Endothelial dysfunction links thrombotic microangiopathy to steroid-refractory graft-versus-host disease (GVHD) after allogeneic stem-cell transplantation. We aimed to assess if the simple formula-lactate dehydrogenase (U/L) × creatinine (mg/dL)/thrombocytes (10(9) cells per L)-termed the Endothelial Activation and Stress Index (EASIX), might be valuable for the prediction of death in patients with acute GVHD after allogeneic stem-cell transplantation. METHODS: For this retrospective analysis, we analysed a training cohort (in Germany) and three validation cohorts (in Germany and the USA) of patients with acute GVHD who had received consecutive allogeneic stem-cell transplantation...
July 18, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28712940/efficacy-pharmacokinetics-and-safety-of-the-biosimilar-ct-p10-compared-with-rituximab-in-patients-with-previously-untreated-advanced-stage-follicular-lymphoma-a-randomised-double-blind-parallel-group-non-inferiority-phase-3-trial
#12
Won Seog Kim, Christian Buske, Michinori Ogura, Wojciech Jurczak, Juan-Manuel Sancho, Edvard Zhavrid, Jin Seok Kim, José-Ángel Hernández-Rivas, Aliaksandr Prokharau, Mariana Vasilica, Rajinish Nagarkar, Dzhelil Osmanov, Larry W Kwak, Sang Joon Lee, Sung Young Lee, Yun Ju Bae, Bertrand Coiffier
BACKGROUND: Studies in patients with rheumatoid arthritis have shown that the rituximab biosimilar CT-P10 (Celltrion, Incheon, South Korea) has equivalent efficacy and pharmacokinetics to rituximab. In this phase 3 study, we aimed to assess the non-inferior efficacy and pharmacokinetic equivalence of CT-P10 compared with rituximab, when used in combination with cyclophosphamide, vincristine, and prednisone (CVP) in patients with newly diagnosed advanced-stage follicular lymphoma. METHODS: In this ongoing, randomised, double-blind, parallel-group, active-controlled study, patients aged 18 years or older with Ann Arbor stage III-IV follicular lymphoma were assigned 1:1 to CVP plus intravenous infusions of 375 mg/m(2) CT-P10 or rituximab on day 1 of eight 21-day cycles...
July 13, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28693986/do-we-perform-better-when-we-increase-red-blood-cells
#13
Stephane Perrey
No abstract text is available yet for this article.
July 7, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28687420/hepatic-adverse-event-profile-of-inotuzumab-ozogamicin-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukaemia-results-from-the-open-label-randomised-phase-3-ino-vate-study
#14
Hagop M Kantarjian, Daniel J DeAngelo, Anjali S Advani, Matthias Stelljes, Partow Kebriaei, Ryan D Cassaday, Akil A Merchant, Naohito Fujishima, Toshiki Uchida, Maria Calbacho, Anna A Ejduk, Susan M O'Brien, Elias J Jabbour, Hui Zhang, Barbara J Sleight, Erik R Vandendries, David I Marks
BACKGROUND: The INO-VATE study demonstrated efficacy and safety of inotuzumab ozogamicin versus standard care in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Here, we report the frequency of, and potential risk factors for, hepatotoxicity in patients in this trial and after treatment and subsequent haemopoietic stem-cell transplantation (HSCT). METHODS: In this open-label, phase 3, multicentre, international study, adults with relapsed or refractory, CD22-positive, Philadelphia chromosome (Ph)-positive or Ph-negative B-cell acute lymphoblastic leukaemia who were due to receive first or second salvage treatment were randomly assigned (1:1) via an interactive voice response system to receive inotuzumab ozogamicin (starting dose 1·8 mg/m(2) per cycle [0·8 mg/m(2) on day 1; 0·5 mg/m(2) on days 8 and 15 of a 21-28 day cycle for ≤6 cycles]) or standard care (either fludarabine plus cytarabine plus granulocyte colony-stimulating factor, mitoxantrone plus cytarabine, or high-dose cytarabine)...
July 4, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28687419/selective-liver-toxicity-and-therapeutic-progress-in-acute-lymphoblastic-leukaemia
#15
Renato Bassan
No abstract text is available yet for this article.
July 4, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28863804/investigation-of-a-gene-signature-to-predict-response-to-immunomodulatory-derivatives-for-patients-with-multiple-myeloma-an-exploratory-retrospective-study-using-microarray-datasets-from-prospective-clinical-trials
#16
Manisha Bhutani, Qing Zhang, Reed Friend, Peter M Voorhees, Lawrence J Druhan, Bart Barlogie, Pieter Sonneveld, Gareth J Morgan, James T Symanowski, Belinda R Avalos, Edward A Copelan, Saad Z Usmani
BACKGROUND: Immunomodulatory derivatives (IMiDs), along with proteasome inhibitors, are key components of treatment regimens for multiple myeloma. Nonetheless, outcomes vary among treated individuals. Drug-specific gene-expression profile (GEP) signatures that aid the prediction of favourable and unfavourable outcomes can provide patients with the most effective therapy for their individual disease. We aimed to develop and validate a gene expression signature to suggest which patients would benefit most from IMiD-based therapies...
September 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28863803/xxvi-congress-of-the-international-society-on-thrombosis-and-haemostasis
#17
Lan-Lan Smith
No abstract text is available yet for this article.
September 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28863802/reply-to-correspondence-do-big-numbers-assure-high-quality-of-data
#18
LETTER
Claudia Allemani, Audrey Bonaventure, Rhea Harewood, Veronica Di Carlo, Michel P Coleman
No abstract text is available yet for this article.
September 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28863801/research-on-biosimilars-pivotal-trials-and-principles
#19
LETTER
Wojciech Jurczak, Arnold G Vulto, Jutta Amersdorffer, Won S Kim, Bertrand Coiffier
No abstract text is available yet for this article.
September 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28863800/conflicts-of-interest-in-twitter
#20
LETTER
Victoria Kaestner, Audrey Brown, Derrick Tao, Vinay Prasad
No abstract text is available yet for this article.
September 2017: Lancet Haematology
journal
journal
49595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"